替罗非班在非ST段抬高型心肌梗死患者介入术中应用的有效性研究

目的研究非ST段抬高型心肌梗死(NSTEMI)患者经皮冠状动脉介入术(PCI)中应用替罗非班的有效性。方法将145例行PCI的非ST段抬高心肌梗死患者随机分为A组(受试组,73例)和B组(对照组,72例)。A组PCI术前给予替罗非班+术中给予推注普通肝素70 U/kg,B组术中推注普通肝素100 U/kg。比较两组射血分数和不良心血管事件:再发胸痛(包括心绞痛、心肌梗死)。结果术前两组患者在年龄、性别构成、危险因素、心功能分级、血管病变指数等临床特点方面差异均无统计学意义(P>0.05),具有可比性。住院及随访期间再发胸痛:A组2例,B组8例。两组复合心血管事件发生率比较差异有统计学意义(P<0.05)。A组、B组的射血分数分别为47.0%±6.4%、56.2%±5.1%,两组比较差异有统计学意义(P<0.05)。结论 NSTEMI患者介入术中使用替罗非班疗效显著。

Efficacy of tirofiban in percutaneous coronary intervention for NSTEMI

Objective To investigate the efficacy of tirofiban for patients with NSTEMI undergoing percutaneous coronary interventional therapy （PCI）. Methods 145 patients with NSTEMI were randomized into group A （n = 73 ） and group B （ n = 72）. Group A was given tirofiban before PCI and then normal heparin 70 U/kg iv during operation,group B was given heparin 100 U/kg iv during operation. Ejection fraction and the main adverse cardiac events （MACE）-recurrence of chest pain（ including angina pectoris and myocardial infarction）were recorded and analyzed. Results Clinical characteristics （including age, sex,risk factors, et al）of the two groups were comparable. During the in-hospital and follow-up visits period ：there were 2 and 8 cases of recurrent chest pain in group A and group B. The ejection fraction of group A and group B were 47.0% ＋ 6.4% and 56. 2% -＋ 5. 1%. There were significant differences between the two groups in terms of MACE （ P 〈 0.05 ） and the ejection fraction （ P 〈 0. 05 ）. Conclusion Tirofiban has significant effects on NSTEMI patients during operation.